<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645746</url>
  </required_header>
  <id_info>
    <org_study_id>R5069-HV-1810</org_study_id>
    <secondary_id>2018-000651-41</secondary_id>
    <nct_id>NCT03645746</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN5069 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of single
      ascending doses of REGN5069 administered intravenously (IV) and subcutaneously (SC) in
      healthy male and female participants.

      The secondary objectives of the study are to characterize the pharmacokinetics (PK) profile
      of single IV and SC doses of REGN5069 in healthy participants and assess the immunogenicity
      of REGN5069 in healthy participants administered single IV or SC doses of REGN5069
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 23, 2018</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From baseline up to week 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>From baseline up to week 36</time_frame>
    <description>As measured by chemistry, hematology and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of vital signs abnormalties</measure>
    <time_frame>From baseline up to week 36</time_frame>
    <description>As measured by heart rate, blood pressure, body temperature and respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of standard 12-lead electrocardiogram (ECG) abnormalties</measure>
    <time_frame>From baseline up to week 36</time_frame>
    <description>As measured by heart rate, PR, complex of Q, R, and S waves [QRS], QT-intervals, and QTc</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of REGN5069 in serum over time</measure>
    <time_frame>From baseline up to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA)</measure>
    <time_frame>From baseline up to week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 will receive a single IV dose of REGN5069 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 will receive a single sequential ascending IV dose of REGN5069 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 will receive a single sequential ascending IV dose of REGN5069 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4 will receive a single sequential ascending IV dose of REGN5069 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5 will receive a single SC dose of REGN5069 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 6 will receive a single sequential ascending SC dose of REGN5069 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 7 will receive a single sequential ascending IV dose of REGN5069 or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN5069</intervention_name>
    <description>REGN5069 will be administered by IV infusion or SC injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-matching REGN5069</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Participant is judged by the investigator to be in good health based on medical
             history, physical examination, vital sign measurements, and ECG performed at screening
             and/or prior to study drug dosing

          -  Participant is in good health based on laboratory safety testing obtained at the
             screening visit

          -  Willing and able to comply with clinic visits and study-related procedures

          -  Provide informed consent signed by study participant or legally acceptable
             representative

        Key Exclusion Criteria:

          -  History of clinically significant cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, psychiatric or neurological disease

          -  Has any physical examination findings and/or history of any illness that might
             confound the results of the study or poses an additional risk to the subject by study
             participation

          -  Hospitalization for any reason within 60 days of the screening visit

          -  Current cigarette smoker or former smoker (cigarettes or e-cigarettes) who stopped
             smoking within 3 months prior to screening

          -  History of drug or alcohol abuse within a year prior to the screening visit

          -  Presence of HIV, hepatitis B, or hepatitis C seropositivity at screening or within 3
             months prior to dosing with the exception of false positive screening tests as
             documented by polymerase chain reaction or Western blot

          -  Any malignancy within the past 5 years, except for basal cell or squamous epithelial
             cell carcinomas of the skin or carcinoma in situ of the cervix or anus, that have been
             resected, with no evidence of metastatic disease for 3 years

        Note: Other protocol Inclusion/Exclusion Criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

